Skip to content
Company Analysis

Dynavax Technologies Corporatio DVAX

A comprehensive view of key metrics, scores, and financial health for Dynavax Technologies Corporatio

Overview of Dynavax Technologies Corporation

DVAX NMS
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech
Dynavax Technologies Corporation (DVAX), in the Drug Manufacturers - Specialty & Generic industry, last closed at $15.50, about 67.7% overvalued vs fair value, +38.8% 1Y return, placing in the top 25% of its sector.
USD 15.50
0.00%
(Delayed)
• Vol 90d: 58.6%
52-Week Range
Enterprise Value
$1.94B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Excellent
Growth
Fair
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Excellent
Completeness: 82%
Confidence: 85%
Updated: Jul 5
Top Beats
No strong beats yet

Quick Facts

Website https://www.dynavax.com
HQ EmeryVille, CA
Employees 405
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$5
$5
$5
Current: $15.50 -68% vs base

Engine Room Money Flow™

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$277.2M
19.4%%
Gross Profit
$227.8M
25.1%%
R&D Expense
$61.5M
12.1%%
Operating Income (EBIT)
$37.6M
1475.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
176.7%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
1/3
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Dynavax Technologies Corporatio's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
58
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
49
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 94% Coverage
Trade-Off Triangle Visualization A ternary plot showing DVAX's balance between Growth (30.0%), Profitability (37.0%), and Safety (32.9%). Growth 30% Safety 33% Profitability 37%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

53th percentile vs peers
54
Key Signals
Rev Growth YoY 19.4% 77p EPS Growth YoY 5.13 92p Revenue CAGR 3Y -14.2% 13p EPS CAGR 3Y -29.2% 19p
Strengths
  • EPS Growth YoY in top 20% of peers (5.13, 92th percentile)
  • Gross Profit Margin in top 20% of peers (82.2%, 84th percentile)
  • FCF Margin in top 20% of peers (21.7%, 83th percentile)
  • Current Ratio in top 20% of peers (10.80, 95th percentile)
Risks

No significant risks identified for this axis.

Profitability

65th percentile vs peers
66
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

58th percentile vs peers
59
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Dynavax Technologies Corporatio.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$5.01
- - -
-67.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000